Headlands Research has acquired a Massachusetts–based clinical research site specialised in neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
The Headlands Research Eastern Massachusetts site is set to deepen the neurology research capabilities of the expanding network of multinational trial sites.
With a focus on diversity, quality, and advanced technology, the site aims to improve the lives of people through new medical therapies.
Headlands Research CEO Cathy Collins said: “With its longstanding focus on memory and movement disorders, Headlands Research Eastern Massachusetts strengthens the breadth and depth of our existing neurology speciality research.
“We are proud to welcome Headlands Research Eastern Massachusetts to our expanding network of clinical trial sites, helping to make clinical trials and the innovative therapies they provide accessible to more people.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSee Also:
The research site is led by founder and principal investigator Dr. Donald Marks.
Marks currently serves at Beth Israel Deaconess Hospital – Plymouth, as a staff in neurology division.
Marks has expertise in the diagnosis and treatment of Alzheimer’s disease, Parkinson’s disease, and related disorders.
Marks said: “My team and I are proud of our ability to provide compassionate care for patients and families facing the impact of neurodegenerative diseases.
“Through our research, we can help fill the gap in the availability of disease-modifying treatments and effective long-term symptomatic therapies.
“Joining Headlands Research increases the number of clinical trials and innovative, investigational treatments available for our patient population.”
The company is also planning to expand its network of clinical trial sites throughout the year.
